



## **Exelixis Announces February 14 Webcast of Presentation at the BIO CEO & Investor Conference**

February 7, 2011

SOUTH SAN FRANCISCO, Calif., Feb 07, 2011 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael Morrissey, Ph.D., the company's president and chief executive officer, will present at the upcoming BIO CEO & Investor Conference at 11:30 a.m. EST / 8:30 a.m. PST on Monday, February 14, 2011 in New York. Dr. Morrissey will discuss the company's development plans and priorities for cabozantinib (XL184), future data presentations and corporate strategy, and provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors at [www.exelixis.com](http://www.exelixis.com).

### **About Exelixis**

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo for several compounds in its pipeline. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

SOURCE: Exelixis, Inc.

Exelixis, Inc.  
Charles Butler, 650-837-7277  
Vice President, Investor Relations and Corporate Communications  
[cbutler@exelixis.com](mailto:cbutler@exelixis.com)